Unlike IKZF1, PAX5 alterations do not appear to impact clinical outcomes, however, the PAX5 mutations may be driver mutations in B-ALL leukemogenesis and play a role in susceptibility of B-ALL [67, 68]. Here, IKZF1 is linked to precursor B-cell acute lymphoblastic leukemia.